Regulatory-approved MS therapies, such as IFN-β1a and IFN-1b (IFN-β), glatiramer acetate, mitoxantrone and natalizumab, are all reasonably effective at attenuating disease progression. These ...

18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it thinks ...

In multiple sclerosis, the ability of clinicians to provide a prognosis for a patient and the design and interpretation of clinical trials both rely heavily on prognostic factors identified from ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk.

Multiple sclerosis articles from across Nature Portfolio Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the protective myelin sheaths that surround nerve ...